Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation
- PMID: 11861434
Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation
Abstract
Background: Despite current interest in the biology and diagnostic applications of cell-free DNA in plasma and serum, the cellular origin of this DNA is poorly understood. We used a sex-mismatched bone marrow transplantation model to study the relative contribution of hematopoietic and nonhematopoietic cells to circulating DNA.
Methods: We studied 22 sex-mismatched bone marrow transplantation patients. Paired buffy coat and plasma samples were obtained from all 22 patients. Matching serum samples were also obtained from seven of them. Plasma DNA, serum DNA, and buffy coat were quantified by real-time PCR of the SRY and beta-globin gene DNA. To investigate the effects of blood drawing and other preanalytical variables on plasma DNA concentrations, blood samples were also collected from 14 individuals who had not received transplants. The effects of blood sampling by syringe and needle, centrifugation, and time delay in blood processing were studied.
Results: The median percentage of Y-chromosome DNA in the plasma in female patients receiving bone marrow from male donors (59.5%) differed significantly (P <0.001) from that in the male patients receiving bone marrow from female donors (6.9%). This indicated that plasma DNA in the bone marrow transplantation recipients was predominantly of donor origin. Compared with paired plasma samples, serum samples had a median 14-fold higher DNA concentration, with the additional DNA being of donor origin. Control experiments indicated that none of the three tested preanalytical variables contributed to a significant change in cell-free DNA concentration.
Conclusions: After bone marrow transplantation, the DNA in plasma and serum is predominantly hematopoietic in origin. Apart from the biological implications of this observation, this finding suggests that plasma and serum can be used as alternative materials for the study of postbone marrow transplantation chimerism.
Similar articles
-
[Evaluation of hematopoietic chimerism after allogeneic bone marrow transplantation by modern molecular techniques (STR-PCR and RQ-PCR)--single center].Przegl Lek. 2010;67(12):1282-91. Przegl Lek. 2010. PMID: 21591354 Polish.
-
Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism.Clin Chem. 1999 Oct;45(10):1741-6. Clin Chem. 1999. PMID: 10508119 Clinical Trial.
-
Human mesenchymal stem cells are not of donor origin in patients with severe aplastic anemia who underwent sex-mismatched allogeneic bone marrow transplant.J Hematother Stem Cell Res. 2002 Dec;11(6):977-84. doi: 10.1089/152581602321080646. J Hematother Stem Cell Res. 2002. PMID: 12590713
-
Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.Bone Marrow Transplant. 1995 Dec;16(6):823-9. Bone Marrow Transplant. 1995. PMID: 8750276
-
Presence of donor-derived DNA and cells in the urine of sex-mismatched hematopoietic stem cell transplant recipients: implication for the transrenal hypothesis.Clin Chem. 2009 Apr;55(4):715-22. doi: 10.1373/clinchem.2008.113530. Epub 2008 Oct 30. Clin Chem. 2009. PMID: 18974360
Cited by
-
Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients.Int J Mol Sci. 2023 Dec 2;24(23):17073. doi: 10.3390/ijms242317073. Int J Mol Sci. 2023. PMID: 38069396 Free PMC article. Review.
-
Quantitative characterization of tumor cell-free DNA shortening.BMC Genomics. 2020 Jul 10;21(1):473. doi: 10.1186/s12864-020-06848-9. BMC Genomics. 2020. PMID: 32650715 Free PMC article.
-
Clinical applications and perspectives of circulating tumor DNA in gastric cancer.Cancer Cell Int. 2024 Jan 6;24(1):13. doi: 10.1186/s12935-024-03209-4. Cancer Cell Int. 2024. PMID: 38184573 Free PMC article. Review.
-
Liquid biopsy leads to a paradigm shift in the treatment of pancreatic cancer.World J Gastroenterol. 2022 Dec 14;28(46):6478-6496. doi: 10.3748/wjg.v28.i46.6478. World J Gastroenterol. 2022. PMID: 36569270 Free PMC article. Review.
-
Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management.Cancers (Basel). 2022 Feb 8;14(3):851. doi: 10.3390/cancers14030851. Cancers (Basel). 2022. PMID: 35159118 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous